Back to Search Start Over

Genetically-programmed, mesenchymal stromal cell-laden & mechanically strong 3D bioprinted scaffolds for bone repair.

Authors :
Abu Awwad HAM
Thiagarajan L
Kanczler JM
Amer MH
Bruce G
Lanham S
Rumney RMH
Oreffo ROC
Dixon JE
Source :
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2020 Sep 10; Vol. 325, pp. 335-346. Date of Electronic Publication: 2020 Jul 03.
Publication Year :
2020

Abstract

Additive manufacturing processes used to create regenerative bone tissue engineered implants are not biocompatible, thereby restricting direct use with stem cells and usually require cell seeding post-fabrication. Combined delivery of stem cells with the controlled release of osteogenic factors, within a mechanically-strong biomaterial combined during manufacturing would replace injectable defect fillers (cements) and allow personalized implants to be rapidly prototyped by 3D bioprinting. Through the use of direct genetic programming via the sustained release of an exogenously delivered transcription factor RUNX2 (delivered as recombinant GET-RUNX2 protein) encapsulated in PLGA microparticles (MPs), we demonstrate that human mesenchymal stromal (stem) cells (hMSCs) can be directly fabricated into a thermo-sintered 3D bioprintable material and achieve effective osteogenic differentiation. Importantly we observed osteogenic programming of gene expression by released GET-RUNX2 (8.2-, 3.3- and 3.9-fold increases in OSX, RUNX2 and OPN expression, respectively) and calcification (von Kossa staining) in our scaffolds. The developed biodegradable PLGA/PEG paste formulation augments high-density bone development in a defect model (~2.4-fold increase in high density bone volume) and can be used to rapidly prototype clinically-sized hMSC-laden implants within minutes using mild, cytocompatible extrusion bioprinting. The ability to create mechanically strong 'cancellous bone-like' printable implants for tissue repair that contain stem cells and controlled-release of programming factors is innovative, and will facilitate the development of novel localized delivery approaches to direct cellular behaviour for many regenerative medicine applications including those for personalized bone repair.<br />Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest.<br /> (Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-4995
Volume :
325
Database :
MEDLINE
Journal :
Journal of controlled release : official journal of the Controlled Release Society
Publication Type :
Academic Journal
Accession number :
32629135
Full Text :
https://doi.org/10.1016/j.jconrel.2020.06.035